The progression from hypertension to congestive heart failure

Journal of the American Medical Association

Volumn 275, Issue 20, 1996, Pages 1557-1562

  Levy, Daniel ^a,b,c,d,e   Larson, Martin G ^a,c   Vasan, Ramachandran S ^a   Kannel, William B ^c   Ho, Kalon K L ^d  

^a Framingham ^*  (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONGESTIVE HEART FAILURE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VALVULAR HEART DISEASE;

ADULT; AGED; COHORT STUDIES; DIASTOLE; DISEASE PROGRESSION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030002580     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.20.1557     Document Type: Article

References (55)

1. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure: the Framingham Study. N Engl J Med. 1972;287:781-787.
2. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 1989; 10:647-656.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992; 327:669-677.
4. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 1991;121:1852-1853.
5. Kannel WB, Hjortland MC, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol. 1974;34:29-34.
6. Braunwald E. Valvular heart disease. In: Braunwald E, ed. Heart Disease. Philadelphia, Pa: WB Saunders Co; 1992:1007-1077.
7. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
8. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A-13A.
9. Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J Am Coll Cardiol. 1989;13:1219-1239.
10. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989;80:564-572.
11. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension. 1989;13(suppl I):I74-I79.
12. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
13. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1151.
14. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 1986;34:124-130.
15. The Systolic Hypertension in the Elderly Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
16. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338: 1281-1285.
17. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BH, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press Ltd; 1995:253-270.
18. Dawber TR, Meadors GF, Moore FEJ. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41:279-286.
19. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
20. Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
21. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1970;72:813-822.
22. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram; prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med. 1969;71:89-105.
23. Kannel W, Wolf P, Garrison E. The Framingham Study, Section 35: Survival Following Initial Cardiovascular Events. Bethesda, Md: National Institutes of Health; 1988:5.
24. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med. 1971;285:1441-1446.
25. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984:48.
26. SAS Institute I: the LIFETEST Procedure. I: SAS/STAT User's Guide, Version 6. Cary, NC: SAS Institute Inc; 1989:1027-1070.
27. SAS Institute I: the PHREG Procedure. I: SAS Technical Report P-229, SAS/STAT Software: Changes and Enhancements, Release 6.07. Cary, NC: SAS Institute Inc; 1992:433-480.
28. Wackers FJ, Lie KI, Becker AE, Durrer D, Wellens HJ. Coronary artery disease in patients dying from cardiogenic shock or congestive heart failure in the setting of acute myocardial infarction. Br Heart J. 1976;38:906-910.
29. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 1987;60(suppl I):85I-93I.
30. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis, the MILIS Study Group. J Am Coll Cardiol. 1989;14:49-57.
31. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-855.
32. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
33. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med. 1996;156:146-157.
34. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol. 1984;54: 778-782.
35. Soufer R, Wohlgelernter D, Vita NA, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol. 1985;55: 1032-1036.
36. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277-283.
37. Iriarte M, Murga N, Sagastagoitia D, et al. Congestive heart failure from left ventricular diastolic dysfunction in systemic hypertension. Am J Cardiol. 1993;71:308-312.
38. Echeverria HH, Bilsker MS, Myerburg RJ, Kessler KM. Congestive heart failure: echocardiographic insights. Am J Med. 1983;75:750-755.
39. Aguirre FV, Pearson AC,Lewen MK,McCluskey M, Labovitz AJ. Usefulness of Doppler echocardiography in the diagnosis of congestive heart feilure. Am J Cardiol. 1989;63:1098-1102.
40. Wong WF, Gold S, Fukuyama O, Blanchette PL. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol. 1989;63: 1526-1528.
41. Vasan RS, Benjamin EJ, Evans JC, Larson MG, Reiss CK, Levy D. Prevalence and clinical correlates of diastolic heart failure: Framingham Heart Study. Circulation. 1995;92(suppl I):I-665.
42. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
43. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314:1547-1552.
44. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
45. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. N Engl J Med. 1992;327: 685-691.
46. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med. 1991;325:293-302.
47. Hill BA. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
48. Glynn JR. A question of attribution. Lancet. 1993;342:530-532.
49. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
50. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
51. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
52. Eriksson H, Svardsudd K, Caidahl K, et al. Early heart failure in the population: the study of men born in 1913. Acta Med Scand. 1988;223:197-209.
53. Gillum RF. Heart failure in the United States 1970-1985. Am Heart J. 1987;113:1043-1045.
54. Centers for Disease Control and Prevention. Mortality from congestive heart failure - United States, 1980-1990. MMWR Morb Mortal Wkly Rep. 1994;43:77-81.
55. Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 1993;68:1143-1150.